Teva Pharmaceutical Industries Receivables 2010-2024 | TEVA
Teva Pharmaceutical Industries receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company
- Teva Pharmaceutical Industries receivables for the quarter ending September 30, 2024 were $3.462B, a 2.27% increase year-over-year.
- Teva Pharmaceutical Industries receivables for 2023 were $3.408B, a 7.79% decline from 2022.
- Teva Pharmaceutical Industries receivables for 2022 were $3.696B, a 18.39% decline from 2021.
- Teva Pharmaceutical Industries receivables for 2021 were $4.529B, a 1.14% decline from 2020.
Teva Pharmaceutical Industries Annual Receivables
(Millions of US $) |
| 2023 |
$3,408 |
| 2022 |
$3,696 |
| 2021 |
$4,529 |
| 2020 |
$4,581 |
| 2019 |
$5,676 |
| 2018 |
$5,822 |
| 2017 |
$7,128 |
| 2016 |
$7,523 |
| 2015 |
$5,350 |
| 2014 |
$5,408 |
| 2013 |
$5,338 |
| 2012 |
$5,572 |
| 2011 |
$6,213 |
| 2010 |
$5,476 |
| 2009 |
$5,019 |
Teva Pharmaceutical Industries Quarterly Receivables
(Millions of US $) |
| 2024-09-30 |
$3,462 |
| 2024-06-30 |
$3,766 |
| 2024-03-31 |
$3,456 |
| 2023-12-31 |
$3,408 |
| 2023-09-30 |
$3,385 |
| 2023-06-30 |
$3,539 |
| 2023-03-31 |
$3,435 |
| 2022-12-31 |
$3,696 |
| 2022-09-30 |
$3,730 |
| 2022-06-30 |
$4,471 |
| 2022-03-31 |
$4,253 |
| 2021-12-31 |
$4,529 |
| 2021-09-30 |
$4,046 |
| 2021-06-30 |
$4,488 |
| 2021-03-31 |
$4,572 |
| 2020-12-31 |
$4,581 |
| 2020-09-30 |
$4,385 |
| 2020-06-30 |
$4,545 |
| 2020-03-31 |
$5,189 |
| 2019-12-31 |
$5,676 |
| 2019-09-30 |
$5,254 |
| 2019-06-30 |
$5,260 |
| 2019-03-31 |
$5,108 |
| 2018-12-31 |
$5,822 |
| 2018-09-30 |
$5,665 |
| 2018-06-30 |
$6,061 |
| 2018-03-31 |
$6,289 |
| 2017-12-31 |
$7,128 |
| 2017-09-30 |
$7,424 |
| 2017-06-30 |
$7,320 |
| 2017-03-31 |
$7,264 |
| 2016-12-31 |
$7,523 |
| 2016-09-30 |
$8,071 |
| 2016-06-30 |
$5,374 |
| 2016-03-31 |
$5,188 |
| 2015-12-31 |
$5,350 |
| 2015-09-30 |
$5,275 |
| 2015-06-30 |
$5,568 |
| 2015-03-31 |
$5,508 |
| 2014-12-31 |
$5,408 |
| 2014-09-30 |
$5,410 |
| 2014-06-30 |
$5,389 |
| 2014-03-31 |
$5,275 |
| 2013-12-31 |
$5,338 |
| 2013-09-30 |
$5,191 |
| 2013-06-30 |
$5,305 |
| 2013-03-31 |
$5,416 |
| 2012-12-31 |
$5,572 |
| 2012-09-30 |
$5,782 |
| 2012-06-30 |
$5,430 |
| 2012-03-31 |
$6,056 |
| 2011-12-31 |
$6,213 |
| 2011-09-30 |
$5,605 |
| 2011-06-30 |
$5,469 |
| 2011-03-31 |
$5,576 |
| 2010-12-31 |
$5,476 |
| 2010-09-30 |
$5,228 |
| 2010-06-30 |
$4,985 |
| 2010-03-31 |
$5,136 |
| 2009-12-31 |
$5,019 |
| 2009-09-30 |
$4,689 |
| 2009-06-30 |
$4,376 |
| 2009-03-31 |
$4,134 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$19.395B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
